February 23, 2022 -- Dante Labs is partnering with the Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology, and COVID-19.
Protelica, a U.S. biotechnology company, has licensed its library of billions of pronectines, nanoantibodies, and a portfolio of 12 patents to the foundation. As part of the partnership, the Renato Dulbecco Foundation will leverage the Dante platform to identify nanoantibodies and their efficacy for a wide range of applications. Additional R&D activities will be outsourced to Twist Biosciences.
The Renato Dulbecco Foundation was selected to receive government funds of approximately $30 million and will employ at least 100 people, including researchers, collaborators, and employees.
Dante Labs is a global genomic data company building and commercializing a new class of health and longevity applications based on whole-genome sequencing and artificial intelligence.
Financial details of the collaboration were not disclosed.
Copyright © 2022 scienceboard.net